Head to Head Survey: Calidi Biotherapeutics (NYSE:CLDI) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)

Calidi Biotherapeutics (NYSE:CLDI) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Earnings & Valuation

This table compares Calidi Biotherapeutics and Eloxx Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calidi Biotherapeutics	$50,000.00	466.30	-$29.22 million	N/A	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	N/A	N/A

Calidi Biotherapeutics has higher revenue and earnings than Eloxx Pharmaceuticals.

Volatility and Risk

Calidi Biotherapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500.

Institutional and Insider Ownership

12.5% of Calidi Biotherapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 24.3% of Calidi Biotherapeutics shares are held by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Calidi Biotherapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calidi Biotherapeutics	N/A	N/A	-344.45%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for Calidi Biotherapeutics and Eloxx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calidi Biotherapeutics	0	0	3	0	3.00
Eloxx Pharmaceuticals	0	0	0	0	0.00

Calidi Biotherapeutics presently has a consensus price target of $16.67, indicating a potential upside of 1,791.79%. Given Calidi Biotherapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Calidi Biotherapeutics is more favorable than Eloxx Pharmaceuticals.

Summary

Calidi Biotherapeutics beats Eloxx Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.